Fatty liver disease--a practical guide for GPs
- PMID: 23826593
Fatty liver disease--a practical guide for GPs
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), encompassing both simple steatosis and non-alcoholic steato-hepatitis (NASH), is the most common cause of liver disease in Australia. Non-alcoholic fatty liver disease needs to be considered in the context of the metabolic syndrome, as cardiovascular disease will account for much of the mortality associated with NAFLD.
Objective: To provide an approach to the identification of NAFLD in general practice, the distinction between simple steatosis and NASH, and the management of these two conditions.
Discussion: Non-alcoholic steato-hepatitis is more common in the presence of diabetes, obesity, older age and increased inflammation, and is more likely to progress to cirrhosis. Cirrhosis may be complicated by hepatocellular carcinoma or liver failure. Hepatocellular carcinoma has also been described in NASH without cirrhosis. Assessment and treatment of features of the metabolic syndrome may reduce associated cardiovascular mortality. Numerous agents have been evaluated, but weight loss remains the only effective treatment for NAFLD.
Similar articles
-
Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?Prim Care Diabetes. 2010 Oct;4(3):129-37. doi: 10.1016/j.pcd.2010.02.004. Epub 2010 Mar 17. Prim Care Diabetes. 2010. PMID: 20299294 Review.
-
Non-alcoholic fatty liver disease.J Diabetes. 2012 Sep;4(3):266-80. doi: 10.1111/j.1753-0407.2012.00204.x. J Diabetes. 2012. PMID: 22564417 Review.
-
[Treatment of non-alcoholic fatty liver disease].Ned Tijdschr Geneeskd. 2011;155:A3181. Ned Tijdschr Geneeskd. 2011. PMID: 21649947 Review. Dutch.
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome.Proc Nutr Soc. 2010 May;69(2):211-20. doi: 10.1017/S0029665110000030. Epub 2010 Feb 17. Proc Nutr Soc. 2010. PMID: 20158939 Review.
Cited by
-
Coffee Consumption and the Progression of NAFLD: A Systematic Review.Nutrients. 2021 Jul 12;13(7):2381. doi: 10.3390/nu13072381. Nutrients. 2021. PMID: 34371891 Free PMC article.
-
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.Nutrients. 2024 Sep 11;16(18):3061. doi: 10.3390/nu16183061. Nutrients. 2024. PMID: 39339660 Free PMC article. Review.
-
Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease.PPAR Res. 2022 Feb 18;2022:4709300. doi: 10.1155/2022/4709300. eCollection 2022. PPAR Res. 2022. PMID: 35242173 Free PMC article.
-
Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD).BMC Health Serv Res. 2020 Apr 21;20(1):335. doi: 10.1186/s12913-020-05233-2. BMC Health Serv Res. 2020. PMID: 32316984 Free PMC article. Clinical Trial.
-
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial.Nutrients. 2019 Feb 23;11(2):475. doi: 10.3390/nu11020475. Nutrients. 2019. PMID: 30813440 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
